Sarcopenia--a potential target for Angiotensin-converting enzyme inhibition?
Society is ageing. There has been a steady increase in the number of people aged 65 years and over throughout the 20th century and this trend is predicted to continue worldwide. This has resulted in an increase in the incidence of sarcopenia, which is a loss of muscle mass and function with age. Maintenance of muscular function into old age is critical to sustaining normal daily activity and functional independence. Sarcopenia is associated with increased morbidity and mortality. Till now most efforts to counteract sarcopenia have met with limited success. We postulate that targeting the renin-angiotensin system through angiotensin-converting enzyme (ACE) inhibition could play a role in countering sarcopenia. ACE inhibitors could work by preventing mitochondrial decline and improving endothelial function and muscle metabolism. We describe the literature to support our hypothesis that sarcopenia may be a potential therapeutic target for ACE inhibitors.
Sumukadas
Deepa
D
Department of Medicine and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK. d.sumukadas@dundee.ac.uk
Struthers
Allan D
AD
McMurdo
Marion E T
ME
D000375:Aging; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D018482:Muscle, Skeletal / Q000098:blood supply / Q000502:physiology; D009133:Muscular Atrophy / Q000503:physiopathology / Q000517:prevention & control*; D011110:Polymorphism, Genetic; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000235:genetics / Q000502:physiology
D000806:Angiotensin-Converting Enzyme Inhibitors